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Abstract
 
C-reactive protein (CRP) is a serum protein that is massively induced as part of the innate im-
mune response to infection and tissue injury. As CRP has been detected in damaged tissues
and is known to activate complement, we assessed whether apoptotic lymphocytes bound
CRP and determined the effect of binding on innate immunity. CRP bound to apoptotic cells
in a Ca
 
2
 
1
 
-dependent manner and augmented the classical pathway of complement activation
but protected the cells from assembly of the terminal complement components. Furthermore,
CRP enhanced opsonization and phagocytosis of apoptotic cells by macrophages associated
with the expression of the antiinflammatory cytokine transforming growth factor 
 
b
 
. The anti-
inflammatory effects of CRP required C1q and factor H and were not effective once cells had
become necrotic. These observations demonstrate that CRP and the classical complement
components act in concert to promote noninflammatory clearance of apoptotic cells and may
help to explain how deficiencies of the classical pathway and certain pentraxins lead to im-
paired handling of apoptotic cells and increased necrosis with the likelihood of immune re-
sponse to self.
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Introduction
 
The vast majority of the cells of the immune system are
short lived, requiring that billions of dying cells be elimi-
nated per day. Exactly how these cells are removed is
poorly understood, but exposure of different protein, car-
bohydrate, and lipid moieties on cells dying through pro-
grammed pathways (apoptosis) provides signals to phago-
cytes for their rapid ingestion (for review see references 1
and 2). In inflammatory states, serum proteins such as pen-
traxins have been implicated in the removal of damaged
cells (3). Pentraxins are a family of highly conserved cyclic
 
pentameric proteins that include C-reactive protein (CRP)
 
1
 
and serum amyloid
 
 
 
P
 
 
 
component (SAP; for review see ref-
erences 4 and 5). Whereas SAP is constitutively expressed
at low levels in human serum, release of proinflammatory
cytokines such as IL-1 and TNF-
 
a
 
 results in up to a 1,000-
fold elevation of CRP (4, 5).
We previously reported that serum complement facili-
tates the uptake of apoptotic cells by phagocytes in vitro
(6), and others have shown that the acute phase pentraxin
in mice, SAP, facilitates the clearance of chromatin (7). As
deficiencies in the early complement components and
acute phase pentraxins predispose humans and mice to lu-
pus-like diseases (8–10) and an increased number of apop-
totic cells are observed in the kidneys of C1q-deficient
(C1qd) mice (10), we attempted to define the relationship
between these serum proteins, apoptotic cells, and phago-
cytosis. Here we report that human CRP amplifies early
classical pathway activation, inhibits the assembly of the
terminal complement components, and promotes op-
sonization of apoptotic cells associated with the expression
of TGF-
 
b
 
, an antiinflammatory cytokine, by macrophages.
Based on these observations, we propose that a key func-
tion of CRP is to promote the clearance of dying cells.
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Abbreviations used in this paper:
 
 C1qd, C1q-deficient; CRP, C-reactive
protein; FH, factor H; HIS, heat-inactivated sera; MAC, membrane at-
tack complex; NHS, normal human sera; PI, propidium iodide; SAP, se-
rum amyloid P component; SLE, systemic lupus erythematosus; snRNPs,
small nuclear ribonucleoproteins. 
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Materials and Methods
 
Antibodies and Reagents.
 
Purified human C1q, factor H (FH),
C1qd human serum, mAbs to C3bi, C1q, and a neoantigen cre-
ated by the formation of the membrane attack complex (MAC;
C5-9), anti–Sc5-9, were purchased from Quidel Corp. C1qd se-
rum had the following properties (normal range in parenthesis):
CH50 179 U/ml when reconstituted with 100 
 
m
 
g/ml C1q (
 
$
 
40
U/ml) and APH50 348 U/ml (
 
$
 
50 U/ml). Two sera with low
or absent FH were provided by Dr. C.D. West (Children’s Hos-
pital Research Foundation, Cincinnati, OH). Serum 1 had a par-
tial FH deficiency (FHlo) [3.7 (37–68 mg/dl)], with C3 
 
5
 
 23.7
(83–177); factor B 
 
5
 
 9.0 (13.3–31.5); C5 
 
5 
 
3.1 (3.8–7.6); C6 
 
5
 
5.9 (4.0–6.9); C7 
 
5 
 
4.5 (3.5–7.9); C8 
 
5 
 
3.4 (3.0–5.8); and 9 
 
5
 
3.4 (2.5–7.5). Serum 2 had a complete (no protein detected) FH
deficiency with C3 
 
5 
 
8.3; factor B 
 
5 
 
4.5; C5 
 
5 
 
1.1; C6 
 
5 
 
3.3;
C7 
 
5 
 
5.1; C8 
 
5 
 
2.0; and C9 
 
5 
 
0.7. mAbs to Fas (CH11), CD14,
and a polyclonal sheep antiserum to FH were purchased from
Upstate Biotechnology, Jackson ImmunoResearch Laboratories,
and The Binding Site, respectively. Human CRP and rabbit
polyclonal anti–human CRP were purchased from Calbiochem.
Annexin V and propidium iodide (PI) were obtained from Trevi-
gen, Inc. The following secondary reagents were used: biotiny-
lated or FITC-, PE-, or Cy5-conjugated sheep anti–mouse IgG,
goat anti–human IgG, donkey anti–rabbit IgG, goat anti–sheep
IgG, and streptavidin (Jackson ImmunoResearch Laboratories or
Santa Cruz Biotechnology, Inc.). Appropriate isotype controls
were purchased from Sigma-Aldrich. Human autoantibodies rela-
tively monospecific for Sm RNP or antiribosomal
 
 
 
P proteins
were selected from well characterized patient sera (11, 12).
The anti-CRP and anti-FH antisera were verified to be mono-
specific when tested against normal serum and cell lysates by
Western blotting, whereas the anti-C3bi antibody bound to C3b
as well as C3bi (not shown). For that reason, the specificity will
be referred to as C3b/bi. SDS-PAGE and Coomassie blue stain-
ing confirmed purity of the isolated CRP and FH proteins (not
shown).
 
Cell Culture and Apoptosis Induction.
 
Peripheral blood–derived
T cells from normal donors or Jurkat T cells were cultured in
RPMI 1640 medium supplemented with 10% FBS, 
 
l
 
-glutamine,
and penicillin–streptomycin as described (6). Normal T cells were
activated by incubation with 2 
 
m
 
g/ml PHA for 24 h. Nonadher-
ent cells were collected and washed and then cultured at 10
 
6
 
cells/ml for 5 d in medium containing 50 U/ml of human re-
combinant IL-2 (Chemicon International, Inc.).
Apoptosis of Jurkat T cells or activated peripheral blood–
derived T cells was induced by incubation with 50 ng/ml of an
agonist anti-Fas mAb, CH11, or 0.1–0.5 
 
m
 
g/ml staurosporine
(Sigma-Aldrich) for 4–6 h. The percentage of early and late ap-
optotic cells was quantified by flow cytometry analysis using an-
nexin V and PI according to the manufacturer’s instructions and
was routinely 70–80%. Distinction between apoptotic and ne-
crotic cells was based on exclusion of trypan blue as determined
by light microscopy. Necrosis was induced by heating cells to
65
 
8
 
C for 1 h or by repeat freeze–thaw cycles (13).
 
Complement and CRP Binding Studies.
 
Normal human sera
(NHS) and other sera used for complement binding and activa-
tion were stored at 
 
2
 
70
 
8
 
C in small aliquots. Where appropriate,
complement was inactivated by heating to 56
 
8
 
C for 30 min (heat-
inactivated sera [HIS]). Complement binding studies were per-
formed by incubation of 10
 
6
 
 cells with 100 
 
m
 
l of medium con-
taining 20% human serum in TC buffer (140 mM NaCl, 2 mM
CaCl
 
2
 
, 10 mM Tris, pH 8.0 or 7.4, supplemented with 1 mM
Mg
 
2
 
1
 
 and 1% BSA) for 30 min at 37
 
8
 
C. CRP binding studies
 
were performed by incubation of 10
 
6
 
 cells with CRP in TC
buffer for 30 min at room temperature. All subsequent wash steps
were performed in the presence of TC buffer, as CRP requires
Ca
 
2
 
1
 
 for binding (14).
 
Flow Cytometry, Immunofluorescence, and Confocal and Western
Blot Analysis.
 
Antibody staining was performed by incubation
of the cells with antibodies for 30 min at 4
 
8
 
C. Flow cytometry
was performed on a FACScan™ instrument operating with
CELLQuest™ software (Becton Dickinson) as described previ-
ously (6). Dead cells and debris were excluded from analysis. Data
were displayed on a logarithmic scale of increasing fluorescence
intensity, and each histogram plot was generated from at least 10
 
4
 
events.
Live and apoptotic cells were cytocentrifuged onto glass slides.
The glass-adherent cells were fixed with 2% paraformaldehyde,
permeabilized with 99% methanol, and, in some cases, counter-
stained with 5 
 
m
 
g/ml of PI. Incubation with CRP, annexin V, or
antibodies was performed as described above, either in the fluid
phase before cytocentrifugation or after fixation and permeabiliza-
tion. Cells were stained with the appropriate antibodies or ligands
and viewed either by immunofluorescence (Nikon Eclipse E600)
or confocal (Zeiss LSM 510 laser scanning microscope) micros-
copy. Western blot analysis was performed as described previously
(15) and developed using an ECL kit (Amersham Pharmacia Bio-
tech) according to the manufacturer’s instructions.
 
Macrophage Phagocytosis.
 
Human macrophages were isolated
from peripheral blood monocytes of normal donors and cultured
on 12-well plastic dishes for 7 d as described previously (6). To
quantify macrophage phagocytosis of apoptotic cells, a flow cyto-
metric assay modified from reference 16 was developed. In brief,
Jurkat cells were labeled with the dye TAMRA (5- (and 6)-car-
boxy tetramethyl rhodamine succinimidyl ester; Molecular
Probes) according to the manufacturer’s instructions. Apoptosis
was induced by staurosporine as above and incubated with serum
factors for 30 min at 37
 
8
 
C. 10
 
6
 
 labeled cells were then incubated
with 
 
z
 
3.5 
 
3
 
 10
 
6
 
 adherent macrophages for 1 h at 37
 
8
 
C in the
absence of serum. After extensive washing, monolayers were re-
leased with trypsin–EDTA, and the macrophages were stained
with FITC–anti-CD14 mAb and analyzed by two-color flow cy-
tometry. Macrophages were gated by forward and side scatter and
CD14 positivity. Apoptotic cells that were not bound or internal-
ized were excluded by this gating. The percentage of macro-
phages that bound or ingested TAMRA-labeled target cells was
calculated. In some experiments, phagocytosis of apoptotic cells
was verified by counting the number of surface-bound and inter-
nalized cells by light microscopy as described (6).
 
Cytokine Assays.
 
2 
 
3 
 
10
 
6
 
 target cells were preincubated with
CRP and/or serum as above, washed, and then incubated with
adherent macrophages at a 2:1 ratio for 16 h at 37
 
8
 
C in 10% heat-
inactivated FCS. The culture medium was collected, briefly cen-
trifuged, and tested for the presence of TNF-
 
a
 
 or TGF-
 
b
 
 using
OptEIA™ kits (PharMingen) according to the manufacturer’s in-
structions. Purified standards were obtained from PharMingen.
 
Results
 
Complement Assembles on the Surfaces of Apoptotic Cells and
Leads to Enhanced Cell Lysis.
 
We previously reported that
the C3 cleavage product, C3bi, is bound to the surfaces of
apoptotic cells and that both the classical and alternative 
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complement pathways were required for maximal C3bi
fixation (6). Activation of the early components of comple-
ment promote opsonization and clearance of particles,
whereas activation of the terminal complement compo-
nents are proinflammatory and result in cell lysis and necro-
sis (17). To determine the potential consequences of the
interaction between complement and apoptotic cells, we
first quantified the binding of the early (C1q) and late (C5-9;
the MAC) complement components to apoptotic cells by
flow cytometry.
C1q has previously been detected on apoptotic kerati-
nocytes, although these cells had been fixed before analysis
(18). To determine if C1q bound to unfixed apoptotic
cells, apoptotic Jurkat cells were incubated with 20% NHS.
As shown by representative examples in Fig. 1 A and by ki-
netic studies in Fig. 1 B, C1q bound to the cell surface
within minutes, and evidence of C3 activation (C3b/bi)
and MAC assembly was also detected by 30 min postincu-
bation. Despite the fact that nucleated cells are relatively
resistant to the effects of lysis by the MAC (19), assembly of
the MAC was associated with increasing permeability to PI
over time (Fig. 1 B). Binding of C1q, C3b/bi, and the
MAC and increased cell permeability were not confined to
apoptotic Jurkat T cells, as similar observations were ob-
served with apoptotic peripheral blood–derived human T
cells, although lower C1q binding suggests that C3b/bi
deposition was due to activation of the alternative (6) and/
or lectin pathway (Fig. 1 C).
To determine whether C1q binding was absolutely re-
quired for complement activation, C3b/bi deposition and
the assembly of the MAC were assessed on apoptotic cells
incubated with NHS or C1qd serum. As shown in Fig. 1 A,
right two panels, the MAC was detected on apoptotic cells
incubated with either source of serum, although MAC as-
sembly was lower in C1qd serum. These findings indicate
that C1q is fixed to the surfaces of apoptotic cells and is as-
sociated with complement activation and assembly of the
MAC but that C1q binding is not absolutely required for
downstream complement activation. In the absence of C1q,
complement is presumably activated by the lectin and/or al-
ternative pathways, as also occurs to some extent in normal
serum.
Figure 1. Complement assembles on the surfaces of apoptotic cells and leads to cell lysis. Apoptosis was induced in Jurkat (A and B) and peripheral
blood–derived (C) T cells with staurosporin and then analyzed by flow cytometry for binding of complement components as well as cell permeability to
PI as described in Materials and Methods. In this and subsequent figures, “apoptotic cells” (Apo) include 20–30% live cells (annexin V negative). In A and
B, live or apoptotic cells were incubated with 20% NHS, HIS, or C1qd serum for 30 min before analysis. Gates were set with isotype control antibodies.
In A, cells were analyzed after 20 min for C1q and MAC binding and after 30 min for C3b/bi and MAC binding. In B, cells were analyzed at different
time points as indicated. The mean 6 SE of three experiments is shown. In C, apoptotic cells were incubated with HIS (thin line) or NHS (thick line)
and then analyzed at 30 min except for PI staining, which was evaluated at 2 h. Results are expressed as the change in mean channel fluorescence
(DMCF). The results shown in A and C are representative of three to five experiments. 
1356
 
C-reactive Protein and the Innate Immune Response to Apoptotic Cells
 
Figure 2.
 
CRP binds to the surfaces of
apoptotic cells. (A) Live (a), necrotic (b),
or apoptotic (c–g) T cells were incubated
with purified CRP, 0.5 (d) or 50 
 
m
 
g/ml
(a–c, e–g), for 20 min at room tempera-
ture. Jurkat T cells were used for all ex-
periments except for g, where normal hu-
man T cells were used. Apoptosis was
induced by staurosporin, except for in e,
where anti-Fas was used. Necrosis was in-
duced by heat (65
 
8
 
C for 1 h) as described
in Materials and Methods. CRP binding
was assessed by flow cytometry using ei-
ther isotype control (thin line) or anti-
CRP antibody (thick line). In c, CRP
binding studies were performed in the presence of 10 mM EDTA. The results are expressed as the percentage of cells positive for binding and are repre-
sentative of five individual experiments. (B) Apoptotic Jurkat cells were incubated with CRP (50 
 
m
 
g/ml) as in A and analyzed by two-color flow cytom-
etry with anti-CRP and annexin V. The kinetics of binding are shown in C (mean 
 
6 
 
SD of three experiments). In C, time 0 is taken from the exposure
of cells to the apoptotic stimulus (whereas the kinetics of complement binding in Figs. 1 B and 3 A were performed with cells that were already apop-
totic). (D) Live (a) or apoptotic (b–f) Jurkat cells were incubated with 50 
 
m
 
g/ml CRP. The cells were washed and stained with anti-CRP, followed by
 
CRP Binds to the Surfaces of Apoptotic Cells.
 
CRP is an
acute phase protein that binds to damaged cells and has
been proposed to have a scavenging function, promoting
the removal of cell debris (4, 5). We postulated that it may
play a similar role in the clearance of apoptotic cells. To ex-
amine this question, live, apoptotic, and necrotic cells were
incubated with 0.5 
 
m
 
g/ml (equivalent to the normal serum
concentration; Fig. 2 A, d) or 50 
 
m
 
g/ml (equivalent to a
moderate acute phase response, Fig. 2 A, a–c and e–g) of
purified CRP, washed, and then examined for CRP bind-
ing by flow cytometry. CRP bound not only to necrotic
cells as expected (b) but also to apoptotic Jurkat cells that
had been induced to die by either anti-Fas antibody (e) or
by staurosporine (f) as well as to apoptotic human periph-
eral blood T cells (g). Binding was specific, because EDTA,
which chelates Ca
 
2
 
1
 
 and disrupts CRP–phosphocholine
interactions (14), totally abrogated binding to apoptotic
cells (c).
Annexin V binds to phosphatidylserine that “flips” to the
outer surface of the cell membrane (20, 21). Despite the fact
that 87% of apoptotic Jurkat T cells stained positive for both
annexin V and CRP (Fig. 2 B), the kinetics of binding of
CRP and annexin V were different (Fig. 2 C), and excess
CRP failed to inhibit binding of annexin V (not shown),
suggesting that CRP bound to a molecule other than phos-
phatidylserine on the cell surface. Different patterns of
binding were also detected by confocal microscopy (Fig. 2
D). As shown in Fig. 2 D c, although colocalization (white)
was present on each cell, annexin V (green) and CRP
(blue) staining were, for the most part, distinct, with CRP
staining showing a more particulate pattern (b, c, and e).
In permeabilized cells, CRP has previously been shown
to bind to small nuclear ribonucleoproteins (snRNPs; ref-
erence 22) that are detected by anti-Sm/RNP autoanti-
bodies and, under certain conditions, to chromatin (refer-
ence 23; for review see reference 24). To determine
whether CRP bound to ligands on the surface or within
the cell, immunofluorescence and confocal microscopy
were performed. As shown in Fig. 2 D, CRP failed to stain
the surfaces of live cells (a) but intensely stained the periph-
eries of apoptotic cells, particularly around apoptotic blebs
(b, c, and e). In contrast to permeabilized cells where nu-
clear staining was consistent with binding to chromatin
and/or snRNPs (d and f), staining of the nuclei was not
observed in apoptotic cells (b), even when multiple images
at different planes were examined.
As both snRNPs and chromatin redistribute to apoptotic
blebs (25), we tested whether the blebs “leaked” these po- 
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tential ligands, thereby accounting for the peripheral stain-
ing pattern of CRP. Both immunofluorescence (e) and
flow cytometry (not shown) revealed that very little sn-
RNP was present on the surfaces of the blebs. In permeabi-
lized cells (f), colocalization of CRP and snRNP was ob-
served in the nucleus and also in apoptotic blebs. Finally,
incubation of apoptotic cells with a soluble cell extract
failed to enhance CRP binding to apoptotic cells as assessed
by flow cytometry (not shown). Together, these findings
indicate that CRP likely binds to ligand(s) other than chro-
matin or snRNP on the surfaces of apoptotic cells.
 
CRP Enhances and Sustains Early Classical Pathway Activa-
tion but Attenuates MAC Formation on Apoptotic Cells.
 
CRP has previously been shown to activate complement
by binding to the collagenous tail of C1q (26). We there-
fore examined the role of CRP in binding and activation
of complement on apoptotic cells. When apoptotic cells
were preincubated with serum containing CRP, C1q
binding to the apoptotic cell surface was amplified and sus-
tained over time compared with controls without the ad-
dition of CRP (Fig. 3 A). These findings are consistent
with other models demonstrating that CRP amplifies the
classical complement pathway on the surface of the acti-
vating particle (27, 28).
 
To determine the effect of CRP on other key down-
stream complement components that induce lysis, such as
C3b/bi, ligands for complement receptors, and assembly of
the MAC, we quantified the levels of these proteins on ap-
optotic cells at intervals after incubation with serum contain-
ing normal or elevated concentrations of CRP. As shown in
Fig. 3 B, CRP enhanced C3b/bi deposition on the surfaces
of apoptotic cells as expected from increased classical path-
way activation and the role of FH as a cofactor for the gen-
eration of C3bi but, paradoxically, markedly reduced MAC
assembly. The somewhat lower increment in C3b/bi, as
compared with C1q, recruitment may be explained by the
role of FH in dissociation of the C3 convertase.
 
CRP Reduces MAC Assembly on Apoptotic Cells by Recruit-
ing FH.
 
CRP has been shown to activate the classical
pathway of complement on nucleated cells without activat-
ing the MAC or causing cytolysis (29). As recent studies
have shown that CRP binds to FH (30, 31), a complement
regulatory protein that accelerates the decay of the C3 and
C5 convertases (32), we tested whether CRP recruitment
of FH was responsible for the reduction in MAC formation.
Western blot (Fig. 4 A) and flow cytometry analysis (Fig.
4 B) confirmed that CRP added to normal but not FHlo
serum increased FH binding to apoptotic cells. The greater
 
Cy-5–conjugated (blue, a–c) or PE-conjugated (red, d–f) secondary antibodies. In a–c, the cells were then cytocentrifuged onto glass slides, fixed, and
counterstained with PI (red) and analyzed by confocal microscopy. In d–f, the cells were not counterstained and were analyzed by immunofluorescence.
In c, cells were coincubated with CRP and annexin V–FITC (green) to compare the patterns of staining between CRP and annexin V. In d, apoptotic
cells were permeabilized before incubation with CRP and anti-CRP so as to compare the patterns of binding to apoptotic cells that were not permeabi-
lized (b and e) before exposure to CRP. In e and f, nonpermeabilized (e) or permeabilized (f) apoptotic cells were incubated with 50 
 
m
 
g/ml CRP and an
anti-Sm/RNP–containing antiserum (1:200 dilution). Sm/RNP antibodies were detected using FITC-conjugated goat anti–human IgG (green). Colo-
calization of snRNP and CRP appears yellow. Confocal images a and c are projections of a stack of 12 slices, and b is a single optical slice at 
 
3
 
64 magni-
fication. Magnification for immunofluorescence is 
 
3
 
60. In c, inset 
 
5
 
 
 
3
 
224. 
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difference in FH binding observed by Western as compared
with flow cytometric analysis is most likely explained by
the superior binding of the polyclonal antiserum to dena-
tured protein on Western blots. Interestingly, FH recruit-
ment was reduced in C1qd serum compared with NHS,
with or without added CRP (Fig. 4, A and B). As FH re-
cruitment in NHS could be attributed to enhanced CRP
and/or C3b deposition on apoptotic cells, we sought to de-
termine by flow cytometry whether cell bound CRP could
recruit FH in the absence of other serum factors. As shown
in Fig. 4 C, increased binding of CRP to apoptotic cells
was associated with increased FH detection, thus demon-
strating specific recruitment by CRP.
To determine whether FH was required for the attenua-
tion of MAC formation, we incubated apoptotic cells with
FHlo serum that contained residual functional C3 (Fig. 4
D) and terminal complement components rather than the
total FH-deficient serum, in which the complement com-
ponents were almost completely consumed. As FHlo serum
failed to attenuate MAC deposition (Fig. 4 E) or lysis (Fig.
4 F) on CRP-coated apoptotic cells but this inhibitory ac-
tivity could be restored by the addback of FH (Fig. 4 E),
we conclude that the recruitment of FH by CRP is re-
quired for the attenuation of MAC assembly. Interestingly,
CRP failed to inhibit MAC formation in C1qd serum (Fig.
4 E). This may be explained by reduced C3b/bi deposition
on these cells (reference 6; results not shown), leading to an
overall reduction in FH binding.
 
CRP Enhances Phagocytosis of Apoptotic Cells.
 
We previ-
ously reported that complement activation on the surfaces
of apoptotic cells facilitates uptake of these cells by mac-
rophage CR3 and CR4 receptors (6). In this study, we
have shown that CRP amplified classical pathway comple-
ment activation on the surface of the apoptotic cell. These
findings lead to the prediction that CRP would enhance
phagocytosis of these cells. As shown in Fig. 5, although
isolated CRP that had bound to apoptotic cells failed to in-
crease phagocytosis in the absence of serum, CRP in the
presence of serum markedly increased phagocytosis. This
effect was complement dependent, as no increase was ob-
served when CRP was added to heat-inactivated (not
shown) or C1qd serum. The reason purified C1q did not
fully restore phagocytosis equivalent to that of normal se-
rum is uncertain, but it could be due to partial denaturation
of the commercial preparation, as a higher concentration of
C1q (250 
 
m
 
g/ml) restored phagocytosis (6). These findings
indicate that CRP promotes classical pathway activation,
which, in turn, enhances the phagocytosis of apoptotic
cells. The similar uptake of apoptotic cells in FHlo serum
and NHS is most likely explained by the high level of
binding of C3b and/or C3bi to apoptotic cells in both
sources of serum (Fig. 4 D).
 
CRP Maintains the Expression of Macrophage TGF-
 
b
 
 in the
Presence of Complement.
 
It has been shown that phagocy-
tosis of apoptotic or necrotic cells leads to the synthesis of
anti- or proinflammatory cytokines such as TGF-
 
b
 
 or
TNF-
 
a
 
, respectively (33, 34). To determine the effects of
CRP and complement on macrophage cytokine produc-
tion, TGF-
 
b
 
 and TNF-
 
a
 
 protein concentrations were
quantified by ELISA in culture supernates after the inges-
tion of apoptotic or necrotic cells. As shown in Fig. 6,
phagocytosis of apoptotic cells induced high expression of
TGF-
 
b
 
 in the presence of high CRP and normal serum.
Induction of TGF-
 
b
 
 was not, however, observed in HIS or
C1qd sera, indicating an obligate requirement for comple-
ment in the antiinflammatory effect of interaction between
apoptotic cells and macrophages. As expected, necrotic
cells were potent inducers of TNF-
 
a
 
, an effect that was not
affected by the presence of high CRP. Surprisingly, the ad-
dition of high levels of CRP with apoptotic cells also in-
Figure 3. CRP enhances the
deposition of early components
of complement yet protects ap-
optotic cells against the forma-
tion of the MAC. Apoptotic Jur-
kat cells were incubated with
20% NHS or HIS for the times
shown in the presence (1CRP)
or absence of 50 mg/ml CRP.
The percentage of cells positive
for C1q staining is shown in A
and reflects the mean 6 SE
of three experiments. An IgM
anti–b2-microglobulin antibody
(1Ab) was used as a positive
control for C1q binding to live Jurkat cells in NHS.
Representative flow cytometry histograms of changes in
the binding of C1q, C3b/bi, and MAC to apoptotic
cells in the presence or absence of 50 mg/ml CRP are
shown in B, and the results of 6–10 experiments are
summarized in C. The results in C (mean 6 SD) are pre-
sented as the percentage of cells that bound the comple-
ment factors in the presence of CRP as compared with
binding in the control (20% NHS without added CRP).
*P = 0.03; **P < 0.05; ***P < 0.0001 compared with
control without added CRP. 
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duced TNF-
 
a
 
 in the absence of serum or in C1qd serum
(Fig. 6).
Apoptotic cells incubated in FH-deficient serum had
high levels of bound C3b/bi and the MAC and increased
permeability to PI (Fig. 4) and were efficiently phagocy-
tosed by macrophages (Fig. 5 A). Despite efficient phago-
cytosis of apoptotic cells, the cytokine profile (low TGF-
 
b
 
,
high TNF-a) was similar to that induced by necrotic cells
and was not affected by the presence of high CRP.
Discussion
There is currently considerable interest in the immuno-
logical consequences of phagocytosis and processing of
dead and dying cells (for review see reference 35). Most ev-
idence would suggest that apoptotic cells dying in their
normal microenvironments are phagocytosed by macro-
phages and that this process induces the expression of anti-
inflammatory cytokines such as TGF-b (13, 33, 34, 36). In
contrast, necrotic cells provoke proinflammatory cytokines
and may promote maturation of dendritic cells, leading to
efficient antigen presentation and an immune response (13,
33, 34). We have recently shown that apoptotic cells fix the
C3 component of complement to their surfaces, resulting
in the facilitation of receptor-mediated macrophage phago-
cytosis (6). In this report, we demonstrate that the acute
phase protein, CRP, also binds to the surfaces of apoptotic
cells, resulting in amplification of classical pathway activa-
Figure 4. Protection from complement-mediated lysis requires FH recruitment by CRP. Apoptotic Jurkat cells were incubated with 20% NHS, C1qd
serum, or FH-deficient (FHlo) serum for 30 min in the presence or absence of 50 mg/ml CRP. In A, FH binding (155 kD) was detected by Western
blotting using anti-FH antiserum, biotinylated anti–sheep IgG, and ECL reagents. Protein loading between lanes was compared by Western blotting the
same membrane with antiribosomal P antiserum (P0 is 38 kD). The roles of CRP, C1q, and FH on the percentage of apoptotic cells binding FH (B) and
the MAC (E) were determined by flow cytometric analysis. The mean 6 SE of three experiments is presented. Where indicated by 1, CRP was added
to a concentration of 50 mg/ml or FH was added back to FHlo serum to a concentration of 50 mg/ml. (C) To determine whether CRP could recruit FH
in the absence of C3b or other serum factors, apoptotic Jurkat cells were incubated with purified CRP (0.5 mg/ml, thin line, or 50 mg/ml, thick line),
washed, and then incubated with purified FH (50 mg/ml). The cells were washed and stained with isotype control (dotted lines), anti-CRP (left panel),
or anti-FH (right panel) and analyzed by flow cytometry. (D) Flow cytometric analysis of apoptotic Jurkat cells incubated with FHlo serum demonstrat-
ing C3b/bi binding (thick line) as compared with normal serum (thin line) and isotype control (dotted line). In F, apoptotic Jurkat T cells were incubated
with PI in the presence of NHS (thick line) or FHlo serum (thin line). The experiments in the left panel were performed without added CRP and those
on the right with 50 mg/ml CRP. PI staining was quantified by flow cytometry.1360 C-reactive Protein and the Innate Immune Response to Apoptotic Cells
tion, reduced terminal complement component assembly,
increased phagocytosis by macrophages, and sustained pro-
duction of TGF-b. The classical pathway of complement
and CRP appear to work in concert to promote the clear-
ance of apoptotic cells in an antiinflammatory context.
CRP was initially characterized by its binding to the
C-polysaccharide of Streptococcus pneumonia (37), suggesting
a primary function in clearance of encapsulated bacteria.
However, CRP in certain species does not bind to C-poly-
saccharide (38). Furthermore, the striking degree of se-
quence homology between species and lack of poly-
morphisms within species (39) suggests that the selection
pressures to maintain homeostatic function are more im-
portant than pressures from infectious organisms. Since the
demonstration of CRP deposition predominantly along the
membranes of damaged cells in noninfectious tissue injury
Figure 5. CRP enhances phagocytosis of apoptotic cells. TAMRA-labeled
apoptotic Jurkat cells were incubated with 50 mg/ml CRP and/or 20% HIS,
NHS, C1qd, or FHlo human serum for 30 min. The cells were washed in se-
rum-free medium and then incubated with human macrophages at a ratio of
5:1 for 1 h in the absence of serum. The macrophages were disadhered and
then labeled with an anti-CD14 mAb and analyzed by flow cytometry. The re-
sults are expressed as the percentage of macrophages that bound or internalized
TAMRA-positive cells. A representative experiment is shown in A, and a sum-
mary (mean 6 SE of four experiments) is shown in B. *C1q reconstituted.
Figure 6. Phagocytosis of CRP-adher-
ent apoptotic cells maintains TGF-b
production in the presence of early com-
plement components. Apoptotic or ne-
crotic Jurkat cells were preincubated
with the components indicated for 30
min and then incubated with macro-
phages in medium containing 10% FBS
overnight. The supernatants were col-
lected, and the concentrations of TNF-a
and TGF-b were quantified by ELISA.
The results are presented as the mean 6
SE of triplicates and are representative of
three independent experiments.1361 Gershov et al.
(40), increasing attention has focused on the role of CRP
binding to self-molecules. CRP specifically binds to phos-
phocholine in membrane bilayers (14) as well as to H1-
containing chromatin (23) and snRNPs (22).
In addition to binding to subcellular particles from lysed
or permeabilized cells, our results indicate that CRP binds
to the cell surface membranes of intact apoptotic cells. This
binding was specific, as evidenced by the requirement for
Ca21 and could readily be distinguished from the speckled
nuclear localization detected in permeabilized cells. The in-
tense staining of CRP on nonpermeabilized apoptotic cells
compared with the minimal surface binding of snRNP and
failure to augment CRP binding after the exposure of ap-
optotic cells to cell lysates suggests that CRP bound to a
ligand(s) other than snRNPs or chromatin on the apoptotic
cell surface. Translocation of phosphatidylserine from the
inside to the outside of the cell is an early event in apopto-
sis and can be detected by binding of annexin V (41). In
damaged cells, it has also been proposed that the lipid bi-
layer becomes unpacked, facilitating hydrolysis of phospho-
lipids by cytoplasmic or secretory phospholipase A2 (42).
Kinetic studies revealed that CRP binding to apoptotic
cells occurred later than that of annexin V. In addition,
confocal microscopy showed an even distribution of an-
nexin V along the membranes of early apoptotic cells com-
pared with CRP aggregates observed on apoptotic cells
that had started to bleb. Taken together with the evidence
that CRP binds to lysophosphocholines in a Ca21-depen-
dent manner only in bilayers that have undergone an alter-
ation of normal organization (14), it seems likely that CRP
bound to lysophophospholipids on apoptotic cells.
One of the best known effects of solid phase binding of
CRP is activation of complement (27). Whereas activation
of the classical pathway facilitates opsonization of particles
for phagocytosis, a process that is noninflammatory unless
other receptors such as FcgRs or CD14 are engaged (43–
47), assembly of the MAC results in necrotic cell lysis (17,
48). Furthermore, assembly of late complement compo-
nents may induce sublethal cell injury and the release of
proinflammatory cytokines (49). As activation of the early
and late complement components would be predicted to
have opposing effects on the innate immune response, we
compared the outcome of CRP binding to apoptotic cells
on early and late complement pathways. Levels of CRP
equivalent to that found in an acute phase response (50 mg/
ml) enhanced and sustained the deposition of both C1q
and, to a lesser extent, C3b/bi on the apoptotic cells. The
relatively lower recruitment of C3b/bi may be explained
by the balance between the increased deposition of C3bi
on the activator surface and destabilization of the amplifica-
tion loop, both promoted by FH. Despite amplification of
the classical pathway, CRP paradoxically attenuated the
formation of the MAC on the surfaces of apoptotic cells,
thereby protecting the cells from lysis. This effect was
achieved by the recruitment of FH, a complement regula-
tory protein that accelerates the decay of the C3 and C5
convertases (32). Although a similar, FH-dependent (30)
inhibitory effect of CRP on alternative pathway activation
on Streptococcus pneumonia and artificially sensitized erythro-
cytes has been observed (50, 51), we propose that the con-
trasting effects of CRP on the early and late complement
pathways that act in concert to opsonize and protect apop-
totic cells from lysis is the primary function of this acute
phase protein in early tissue injury.
Elevated levels of CRP in serum also had striking effects
on the phagocytosis of apoptotic cells and quality of cyto-
kines expressed by macrophages that, most likely, dictate the
nature of the immune response to the ingested particle (13,
33, 34). Elevated serum CRP markedly increased phagocy-
tosis of apoptotic cells and maintained TGF-b expression.
Failure of elevated CRP to augment TGF-b beyond that
seen in normal serum is, most likely, explained by near
maximal expression of TGF-b under these experimental
conditions. In contrast, as shown previously (13, 33, 34),
phagocytosis of necrotic cells, including those produced by
exposure to FHlo serum (Fig. 4 F), induced expression of
the proinflammatory cytokine TNF-a. Elevated TNF-a
expression was observed whether or not the necrotic cells
were preincubated with CRP, consistent with studies dem-
onstrating that, once tissue necrosis has already occurred,
CRP does not exert an antiinflammatory effect (52). Al-
though CRP can engage FcgRs in serum-free medium
(53), the failure of isolated CRP or elevated CRP in HIS
to enhance phagocytosis suggests that increased uptake was
mediated predominantly through complement rather than
via Fcg receptors.
The above observations indicate that CRP promotes the
clearance of apoptotic cells, helps to protect the cells from
necrotic lysis through recruitment of FH, and maintains the
cytokine profile antagonistic to an immune response. It
should be emphasized that all of these effects required the
presence of C1q, indicating a pivotal role for the early
complement component(s) in the antiinflammatory effects
of CRP. The cytokine response in C1qd serum was partic-
ularly informative with respect to the known relationship
between C1q deficiency and autoimmunity. The minimal
expression of TGF-b by macrophages incubated with ap-
optotic cells in C1qd serum is either explained by failure of
ligation of C1q receptors or failure of uptake of the apop-
totic cells. In contrast, when CRP levels were elevated in
C1qd serum, TNF-a expression was markedly increased.
These results suggest that, in an acute phase response, mac-
rophage receptor engagement by CRP, and possibly other
ligands, in the absence of coengagement of the C1q recep-
tors exerts a proinflammatory effect. As CRP has recently
been shown to bind to FcgRIIa (53, 54), a receptor associ-
ated with activation of the respiratory burst and a proin-
flammatory cytokine production by macrophages (47), we
propose that it is the engagement of this receptor by CRP
in the absence of serum or in C1qd serum that promotes
TNF-a production but that complement receptors have a
dominant inhibitory effect in normal serum. Experiments
to study this further are underway.
The results of this study also suggest a common mecha-
nism to help explain how early complement pathway and
serum pentraxin deficiencies predispose individuals to sys-1362 C-reactive Protein and the Innate Immune Response to Apoptotic Cells
temic autoimmune disorders such as systemic lupus erythe-
matosus (SLE). Whereas apoptotic cells in central lymphoid
organs would be expected to be rapidly cleared by local
phagocytes, most likely by noncomplement receptors (1,
2), dying cells in the circulation or at sites of tissue injury/
inflammation may not be immediately phagocytosed (55–
58). It is at these sites that the dying cells would bind serum
proteins, including pentraxins, and activate the early com-
ponents of complement. In normal individuals, phagocyto-
sis would be efficiently achieved through complement (6)
as well as other receptors, and the cytokine response is an-
tiinflammatory. In the absence of C1q and other early
complement components, opsonization of apoptotic cells
would be less efficient, providing increased opportunity for
necrotic cell lysis, uptake would be reduced, and the cyto-
kines expressed by macrophages would become proinflam-
matory, promoting an immune response to self.
SLE is a relapsing disease, with exacerbations possibly in-
duced by minor infections. Whereas serum complement
components and CRP normally increase during acute in-
fections, patients with SLE paradoxically demonstrate low
levels of early complement (59) and CRP (60). The results
of this study indicate that deficiency of C1q, as might arise
from inherited deficiency, hypermetabolism, or antibodies
to C1q (61) not only fails to protect apoptotic cells from ly-
sis but also permits the normally protective effect of CRP
to perpetuate the inflammatory response. This may explain
how tolerance to self-antigens is broken.
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